The International yeast meeting
Meet up with Albumedix at the 2017 The International yeast meeting
Albumedix’ albumin-based technologies are both clinically and commercially validated in a number of albumin-enabled pharmaceutical programs by partners. These programs include all from preclinical candidates to marketed products spanning a wide range of therapeutic indications, demonstrating the value and applicability of Albumedix’ recombinant human albumin products and technologies.
Albumedix’s Veltis® drug delivery platform is used in marketed and late-stage clinical drug candidates. Through our partners, Veltis® has been both clinically and commercially validated for its superior performance in optimizing drug dosing across a range of indications.
In addition to the candidates listed in the below pipeline, Veltis® is currently being evaluated by several biotech and pharmaceutical companies, with a number in late-stage feasibility testing.
Similar to our partnered Veltis® drug pipeline, Albumedix’s Recombumin® recombinant albumin products are successfully being used by drug and vaccine developers in more than 10 clinical programs worldwide. This serves as additional validation to the long track-record of superior performance and safety already demonstrated with Recombumin®.
Additionally, Recombumin® is used in several marketed as well as clinical-stage medical device products and cell therapies globally.